The present invention embraces methods for the diagnosis and treatment of learning or mental disorders, as well as the identification of agents useful in the treatment of such disorders based upon the identified involvement of Sarcoplasmic Ca2+-ATPase type 2 Protein in synaptic plasticity and neurotransmitter release in 22qll deletion/DiGeorge Syndrome.
USE OF SARCOPLASMIC CA2+-ATPASE TYPE 2 PROTEIN FOR DIAGNOSING AND TREATING LEARNING OR MENTAL DISORDERS